0001415889-24-013612.txt : 20240517
0001415889-24-013612.hdr.sgml : 20240517
20240517180145
ACCESSION NUMBER: 0001415889-24-013612
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240515
FILED AS OF DATE: 20240517
DATE AS OF CHANGE: 20240517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Winningham Rick E
CENTRAL INDEX KEY: 0001302443
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36033
FILM NUMBER: 24961768
MAIL ADDRESS:
STREET 1: 901 GATEWAY BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Theravance Biopharma, Inc.
CENTRAL INDEX KEY: 0001583107
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET
CITY: GEORGE TOWN, GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
BUSINESS PHONE: 650-808-6000
MAIL ADDRESS:
STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET
CITY: GEORGE TOWN, GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
4
1
form4-05172024_100519.xml
X0508
4
2024-05-15
0001583107
Theravance Biopharma, Inc.
TBPH
0001302443
Winningham Rick E
C/O THERAVANCE BIOPHARMA US, INC.
901 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
true
true
false
false
CHIEF EXECUTIVE OFFICER
0
Ordinary Shares
2024-05-15
4
A
0
2068
9.85
A
1852641
D
Ordinary Shares
3900
I
As Custodian
Ordinary Shares
92567
I
By Trust
Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on May 15, 2024. Transaction was with the Issuer and did not involve an open market transaction.
/s/ Brett A. Grimaud, Attorney-in-Fact
2024-05-17